Nicox SA Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

April 2024 | 50 pages | ID: N93E8DC2934BEN
BAC Reports

Abstracts

Nicox SA Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Nicox SA and its competitors. This provides our Clients with a clear understanding of Nicox SA position in the Pharmaceuticals and Biotechnology Industry.

• The report contains detailed information about Nicox SA that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• Another part of the report is a SWOT-analysis carried out for Nicox SA. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
• The Nicox SA financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
• In the part that describes Nicox SA competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Nicox SA business.

About Nicox SA

Nicox SA, a research pharmaceutical company, engages in the research and development of nitric oxide-donating drugs with superior efficacy and safety profiles in the inflammation, pain and cardiovascular therapeutic areas.

The company seeks to commercialize its products through partnerships and co-development agreements where it maintains future marketing rights for specialist products. NicOx has retained all marketing rights for the U.S. and Asia in addition to co-marketing rights in the European Union and EFTA.

Products

NCX 4016: NCX 4016 is a novel anti-thrombotic and vascular anti-inflammatory nitric oxide-donating agent, which is in phase II clinical trials for the treatment of the symptoms of peripheral arterial obstructive disease (PAOD).

HCT 3012: HCT 3012 is the lead compound in a new class of analgesic and anti-inflammatory drugs, known as CINODs (COXInhibiting Nitric Oxide Donators) designed for the treatment of osteoarthritis. NicOx has planned a comparative clinical study to evaluate the effects of HCT 3012 on arterial blood pressure in patients with mild essential hypertension.

NCX 701: NCX 701 is a nitric oxide-donating analgesic, is in development for acute pain management. The compound is in phase II clinical development.

NCX 1510: NCX 1510 is a nitric oxide-donating drug successfully selected from the joint research program with Biolipox to advance into clinical development for the treatment of allergic rhinitis. In June 2004, NicOx’ partner, Biolipox AB, announced successful phase IIa clinical trial results in allergic rhinitis with NCX 1510.

NCX 1000: NCX 1000 is being developed under a co-development and license agreement with Axcan Pharma for the treatment of chronic liver diseases including portal hypertension and Hepatitis C. Several animal studies have already shown the pharmacological effects of NCX 1000 on portal pressure.

HCT 1026: HCT 1026, a patented nitric oxide-donating derivative of flurbiprofen, is in clinical development for the treatment of Alzheimer’s Disease. In April 2004, NicOx announced that HCT 1026, a novel NO-donating derivative of flurbiprofen, was found to significantly reduce beta-amyloid deposition in the brain of a mouse model of Alzheimer’s Disease, the most common form of dementia in the elderly.

NCX 1020: NCX 1020, a nitric oxide-donating derivative of budesonide is in phase I/IIa clinical trials for the treatment of asthma. NCX 1020 is a new class of inhaled steroids targeted at the treatment of severe respiratory diseases, such as asthma and Chronic Obstructive Pulmonary Disease (COPD).

NCX 1022: NicOx and its partner Ferrer are conducting a program of synthesis and screening of a series of potency NOdonating steroids to identify a new lead development candidate with maximum commercial potential to take into an accelerated development program. The company received positive results from a phase IIa trial for NCX 1022, an ointment for the treatment of seborrheic dermatitis. NCX 1022 is the prototype nitric oxide-donating steroid and is a derivative of the steroid hydrocortisone.

Strategic Collaborations

The company in collaboration with Spain's Ferrer Pharmaceuticals has developed NCX 1022, its anti-inflammatory dermatology product.

The company’s corporate partners include: Axcan Pharma Inc.; Biolipox AB; Merck & Co., Inc.; Ferrer Grupo; and Pfizer Inc.

Biolipox AB: In 2001, NicOx signed a research and co-development agreement for a novel class of nitric oxide-donating respiratory therapeutics with the Swedish research-based company Biolipox.

Axcan Pharma, Inc.: The company has partnership with Axcan Pharma, Inc for the positive phase I clinical results, development of NCX 1000 is advancing into phase II clinical trials for the treatment of portal hypertension, a life threatening complication of chronic liver disease. In 2002, NicOx signed a codevelopment and license agreement for NCX 1000 with Axcan, a North American specialty pharmaceutical company in the gastro-enterology field.

Merck & Co., Inc.: The company has a research collaboration with Merck progressed in evaluating the therapeutic of a series of NicOx’ products. NicOx synthesized a series of nitric oxide-donating compounds which have entered a pre-clinical evaluation program in the laboratories of Merck and of NicOx. In August 2003, NicOx signed a research evaluation agreement with Merck to evaluate selected nitric oxide-donating compounds under NicOx’ intellectual property rights.

Ferrer Grupo: In April 2004, NicOx signed a licensing and co-development agreement with Ferrer Grupo for the research, development and marketing of certain new steroid derivatives for the treatment of dermatological diseases in selected markets. Ferrer has marketing rights for the European Union (including EFTA), Latin America and French-speaking Africa (including Morocco and Algeria) and Egypt. NicOx retains rights to co-market products directly in the European Union and EFTA. NicOx retains all rights for the U.S. and Asia. A joint development committee is coordinating and overseeing all research and development activities.

Pfizer, Inc.: In August, 2004, NicOx signed a research, option, development and licensing agreement with Pfizer, Inc. related to selected proprietary NicOx nitric oxidedonating compounds. Under the agreement, NicOx grants Pfizer an option to acquire an exclusive worldwide license covering early-stage nitric oxide-donating compounds in an undisclosed field.

Significant Events

NicOx SA and Topigen Pharmaceuticals, Inc. have initiated a Phase II trial of TPI 1020, an anti-inflammatory drug candidate developed by NicOx for the treatment of chronic obstructive pulmonary disease (COPD). TPI 1020 is an inhaled nitric oxide-donating derivative of budesonide, a corticosteroid marketed by AstraZeneca plc, of London, under the name ofPulmicort.

History

Nicox SA was founded in 1996.

The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. NICOX SA COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. NICOX SA BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. NICOX SA SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. NICOX SA FINANCIAL ANALYSIS

4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.1. Profitability
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. NICOX SA COMPETITORS AND INDUSTRY ANALYSIS

5.1. Nicox SA Direct Competitors
5.2. Comparison of Nicox SA and Direct Competitors Financial Ratios
5.3. Comparison of Nicox SA and Direct Competitors Stock Charts
5.4. Nicox SA Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Nicox SA Industry Position Analysis

6. NICOX SA NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. NICOX SA EXPERTS REVIEW¹

7.1. Experts Consensus
7.2. Experts Revisions

8. NICOX SA ENHANCED SWOT ANALYSIS²

9. FRANCE PESTEL ANALYSIS²

9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors

10. NICOX SA IFE, EFE, IE MATRICES²

10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix

11. NICOX SA PORTER FIVE FORCES ANALYSIS²

12. NICOX SA VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Nicox SA Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Nicox SA 1-year Stock Charts
Nicox SA 5-year Stock Charts
Nicox SA vs. Main Indexes 1-year Stock Chart
Nicox SA vs. Direct Competitors 1-year Stock Charts
Nicox SA Article Density Chart

1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.

List Of Tables

LIST OF TABLES

Nicox SA Key Facts
Profitability
Management Effectiveness
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Nicox SA Key Executives
Nicox SA Major Shareholders
Nicox SA History
Nicox SA Products
Revenues by Segment
Revenues by Region
Nicox SA Offices and Representations
Nicox SA SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Nicox SA Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Credit Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Nicox SA Capital Market Snapshot
Nicox SA Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Nicox SA Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Nicox SA Consensus Recommendations¹
Analyst Recommendation Summary¹
Price Target Summary¹
Experts Recommendation Trends¹
Revenue Estimates Analysis¹
Earnings Estimates Analysis¹
Historical Surprises¹
Revenue Estimates Trend¹
Earnings Estimates Trend¹
Revenue Revisions¹

ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

• How to use the strengths to take advantage of the opportunities?
• How to use the strengths to reduce likelihood and impact of the threats?
• How to overcome the weaknesses that obstruct taking advantage of the opportunities?
• How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.

Key Factors Examined by PESTEL Analysis:

• Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
• Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
• Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
• Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
• Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
• Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.

Porter Five Forces Analysis

The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

1. What composes a threat of substitute products and services?
2. Is there a threat of new competitors entering the market?
3. What is the intensity of competitive rivalry?
4. How big is the bargaining power of buyers?
5. How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:

• Tangible resources
  • Financial
  • Physical
  • Technological
  • Organizational
• Intangible resources
  • Human
  • Innovation and Creativity
  • Reputation
• Organizational capabilities

The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:

• Valuable?
• Rare?
• Costly to imitate?
• Organized properly?